Cheng Y C, Derse D, Tan R S, Dutschman G, Bobek M, Schroeder A, Bloch A
Cancer Res. 1981 Aug;41(8):3144-9.
2-azido-2'-deoxyarabinofuranosylcytosine (Cytarazid), recently synthesized, was found to inhibit the in vitro growth of several human cell lines by 50% at concentrations ranging from 0.06 to 0.2 microM and to prevent the replication of herpes simplex virus types 1 and 2 by 98% at 50 microM. As determined with HeLa cells, the inhibition of cell growth was partially prevented by 2'-deoxycytidine (dCyd) and cytidine but not by uridine or thymidine. Cytarazid proved resistant to deamination by human cytidine/dCyd deaminases purified from acute myelocytic leukemia blast cells and from liver, a property reflected in the inability of tetrahydrouridine to enhance the cytotoxicity of the compound. Cytarazid served as a substrate for cytoplasmic dCyd kinase partially purified from human peripheral chronic lymphocytic leukemia blast cells. At a concentration of 0.4 mM, the nucleoside analog was phosphorylated 2.6 times more effectively by this enzyme than was dCyd, the Km for Cytarazid being 250 microM. In intact HeLa cells, the triphosphate derivative of Cytarazid was the major drug metabolite formed. In these cells, the analog interfered with the incorporation of radiolabeled thymidine into DNA at a concentration and a time interval at which the incorporation of uridine into RNA and amino acids into protein was not inhibited, suggesting that interference with DNA synthesis is a primary drug effect. Further analysis showed that Cytarazid triphosphate interferes with DNA synthesis in intact HeLa cell nuclei and that it inhibits both the alpha- and beta-DNA polymerases purified from HeLa cells in a manner competitive with deoxycytidine triphosphate, with Ki's of 0.6 and 0.7 microM, respectively. Cytarazid triphosphate was not able to replace deoxycytidine triphosphate for the synthesis of DNA in either intact nuclei or in cell-free preparations; but, in the cell-free assay system, the compound was found to interfere with primer-template activity.
2-叠氮基-2'-脱氧阿拉伯呋喃糖基胞嘧啶(阿糖胞苷)是最近合成的,发现它在浓度为0.06至0.2微摩尔时能抑制几种人类细胞系的体外生长达50%,并在50微摩尔时能阻止单纯疱疹病毒1型和2型的复制达98%。用HeLa细胞测定,2'-脱氧胞苷(dCyd)和胞苷可部分阻止细胞生长的抑制,但尿苷或胸苷则不能。阿糖胞苷对从急性髓细胞白血病原始细胞和肝脏中纯化的人胞苷/dCyd脱氨酶的脱氨作用具有抗性,这一特性表现为四氢尿苷无法增强该化合物的细胞毒性。阿糖胞苷是从人外周慢性淋巴细胞白血病原始细胞中部分纯化的细胞质dCyd激酶的底物。在浓度为0.4毫摩尔时,该核苷类似物被这种酶磷酸化的效率比dCyd高2.6倍,阿糖胞苷的Km为250微摩尔。在完整的HeLa细胞中,阿糖胞苷的三磷酸衍生物是形成的主要药物代谢产物。在这些细胞中,该类似物在不抑制尿苷掺入RNA和氨基酸掺入蛋白质的浓度和时间间隔下,干扰放射性标记的胸苷掺入DNA,这表明干扰DNA合成是该药物的主要作用。进一步分析表明,阿糖胞苷三磷酸在完整的HeLa细胞核中干扰DNA合成,并且它以与脱氧胞苷三磷酸竞争的方式抑制从HeLa细胞中纯化的α-和β-DNA聚合酶,其Ki分别为0.6和0.7微摩尔。阿糖胞苷三磷酸在完整细胞核或无细胞制剂中都不能替代脱氧胞苷三磷酸用于DNA合成;但是,在无细胞测定系统中,发现该化合物会干扰引物-模板活性。